TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO

被引：0
|
作者：
Gladman, D. D.
Coates, L. C.
Wu, J.
Fallon, L.
Hsu, M. A.
Bushmakin, A. G.
Bacci, E.
Cappelleri, J. C.
Helliwell, P.
机构：
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.994
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0774
引用
收藏
页码：1681 / 1681
页数：1
相关论文
共 50 条
  • [1] Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
    Gladman, Dafna D.
    Coates, Laura C.
    Wu, Joseph
    Fallon, Lara
    Bacci, Elizabeth D.
    Cappelleri, Joseph C.
    Bushmakin, Andrew G.
    Helliwell, Philip S.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [2] Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
    Dafna D. Gladman
    Laura C. Coates
    Joseph Wu
    Lara Fallon
    Elizabeth D. Bacci
    Joseph C. Cappelleri
    Andrew G. Bushmakin
    Philip S. Helliwell
    [J]. Arthritis Research & Therapy, 24
  • [3] Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
    Gladman, Dafna
    Coates, Laura
    Wu, Joseph
    Fallon, Lara
    Hsu, Ming-Ann
    Bushmakin, Andrew
    Bacci, Elizabeth
    Cappelleri, Joseph
    Helliwell, Philip
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [4] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
    Strand, Vibeke
    Mease, Philip J.
    Soriano, Enrique R.
    Kishimoto, Mitsumasa
    Salvarani, Carlo
    Saffore, Christopher D.
    Zueger, Patrick
    McDearmon-Blondell, Erin
    Kato, Koji
    Gladman, Dafna D.
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1789 - 1808
  • [5] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
    Vibeke Strand
    Philip J. Mease
    Enrique R. Soriano
    Mitsumasa Kishimoto
    Carlo Salvarani
    Christopher D. Saffore
    Patrick Zueger
    Erin McDearmon-Blondell
    Koji Kato
    Dafna D. Gladman
    [J]. Rheumatology and Therapy, 2021, 8 : 1789 - 1808
  • [6] Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
    Strand, Vibeke
    van Vollenhoven, Ronald F.
    Lee, Eun Bong
    Fleischmann, Roy
    Zwillich, Samuel H.
    Gruben, David
    Koncz, Tamas
    Wilkinson, Bethanie
    Wallenstein, Gene
    [J]. RHEUMATOLOGY, 2016, 55 (06) : 1031 - 1041
  • [7] Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
    Mease, P.
    Hall, S.
    FitzGerald, O.
    van der Heijde, D.
    Merola, J. F.
    Avila-Zapata, F.
    Cieslak, D.
    Graham, D.
    Wang, C.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16): : 1537 - 1550
  • [8] Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept
    Mease, P
    Gottlieb, A
    Woolley, JM
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P2 - P2
  • [9] Patient-Reported Outcomes in Psoriatic Arthritis
    Orbai, Ana-Maria
    Ogdie, Alexis
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2016, 42 (02) : 265 - +
  • [10] THE IMPACT OF ADALIMUMAB VS PLACEBO ON PATIENT-REPORTED OUTCOMES AND UTILITY MEASURES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE PSORIATIC ARTHRITIS
    Strand, V.
    Patel, P.
    Chen, N.
    Lesser, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1718 - 1719
12345